Vanda Pharmaceuticals (VNDA) Research & Development (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Research & Development data on file, last reported at $28.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 20.38% year-over-year to $28.4 million; the trailing twelve-month figure through Mar 2026 stood at $7.1 million (down 92.0% YoY), and the FY2025 full-year result was $14.4 million, down 80.65% from the prior year.
• Research & Development improved to $28.4 million in Q1 2026, from -$65.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $35.7 million in Q1 2025 to a low of -$65.9 million in Q4 2025.
• A 5-year average of $16.5 million and a median of $21.0 million in 2022 frame the typical range for Research & Development.
• Peak annual rise in Research & Development reached 68.82% in 2025, while the deepest fall reached 431.98% in 2025.
• Tracing VNDA's Research & Development over 5 years: stood at $18.5 million in 2022, then jumped by 31.89% to $24.3 million in 2023, then dropped by 18.48% to $19.8 million in 2024, then slumped by 431.98% to -$65.9 million in 2025, then soared by 143.17% to $28.4 million in 2026.
• Business Quant data shows VNDA's Research & Development at $28.4 million in Q1 2026, -$65.9 million in Q4 2025, and $22.6 million in Q3 2025.